Recombinant Human SOST Protein，His

SOST (sclerostin) is a glycoprotein primarily produced by osteocytes and plays a crucial role in bone metabolism and homeostasis. Its primary function is to inhibit the Wnt/β-catenin signaling pathway, which is essential for bone formation. Elevated levels of SOST are associated with conditions such as osteopenia and osteoporosis, making it a significant target for therapeutic interventions in bone-related diseases. Research has revealed that SOST is involved in various physiological processes, including bone remodeling and the regulation of bone density. Additionally, genetic studies have identified mutations in the SOST gene linked to sclerosteosis and van Buchem disease, highlighting its importance in bone density disorders. Given its regulatory role, recombinant SOST proteins are being explored as potential treatments to enhance bone formation or counteract bone density loss. Moreover, understanding the structure-function relationship of SOST and developing effective SOST inhibitors could open new avenues for therapies aiming to combat skeletal diseases and improve overall bone health. The exploration of SOST and its signaling pathways has significant implications not only for the understanding of bone biology but also for developing targeted treatments that can positively impact the quality of life for individuals with bone-related conditions.